Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MGRMNYSE:NSPRNASDAQ:PDEXNASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGRMMonogram Orthopaedics$2.70+1.5%$2.65$1.92▼$4.21$96.36M0.41248,221 shs25,019 shsNSPRInspireMD$2.44+5.3%$2.51$2.07▼$3.80$74.87M0.5939,536 shs5,650 shsPDEXPro-Dex$41.13+4.0%$50.32$16.84▼$70.26$134.13M0.1732,022 shs7,050 shsPYPDPolyPid$3.57+4.7%$2.82$2.30▼$4.49$36.28M1.25120,778 shs100,994 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGRMMonogram Orthopaedics0.00%+4.72%+2.70%-27.52%+29.13%NSPRInspireMD0.00%-7.20%-1.69%-17.14%-8.66%PDEXPro-Dex0.00%-7.81%-8.26%-19.08%+104.76%PYPDPolyPid0.00%+4.28%+24.45%+12.73%-19.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMGRMMonogram Orthopaedics2.9233 of 5 stars3.83.00.00.02.71.70.6NSPRInspireMD2.5055 of 5 stars3.52.00.00.02.22.50.6PDEXPro-Dex3.2242 of 5 stars3.52.00.00.02.22.51.9PYPDPolyPid3.1296 of 5 stars3.65.00.00.03.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMGRMMonogram Orthopaedics 3.50Strong Buy$5.40100.00% UpsideNSPRInspireMD 3.00Buy$4.5084.12% UpsidePDEXPro-Dex 3.00Buy$56.0036.15% UpsidePYPDPolyPid 3.20Buy$11.25215.13% UpsideCurrent Analyst Ratings BreakdownLatest PYPD, NSPR, MGRM, and PDEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.005/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.004/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/18/2025MGRMMonogram OrthopaedicsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.403/18/2025MGRMMonogram OrthopaedicsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.40(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMGRMMonogram Orthopaedics$365.00K263.99N/AN/A$0.43 per share6.28NSPRInspireMD$7.03M10.65N/AN/A$1.83 per share1.34PDEXPro-Dex$64.12M2.09$1.18 per share34.81$9.76 per share4.21PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMGRMMonogram Orthopaedics-$13.74M-$0.45N/AN/AN/AN/A-130.90%-106.38%8/13/2025 (Estimated)NSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/APDEXPro-Dex$2.13M$2.8020.4619.97N/A11.06%21.68%12.40%9/4/2025 (Estimated)PYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-624.10%-129.28%8/13/2025 (Estimated)Latest PYPD, NSPR, MGRM, and PDEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MGRMMonogram Orthopaedics-$0.12-$0.10+$0.02-$0.10N/AN/A5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMGRMMonogram OrthopaedicsN/A7.317.31NSPRInspireMDN/A6.396.05PDEXPro-Dex0.332.581.44PYPDPolyPid0.081.311.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMGRMMonogram Orthopaedics0.45%NSPRInspireMD44.78%PDEXPro-Dex15.28%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipMGRMMonogram Orthopaedics28.10%NSPRInspireMD34.06%PDEXPro-Dex47.50%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMGRMMonogram Orthopaedics2835.69 million24.67 millionNot OptionableNSPRInspireMD5030.64 million18.33 millionOptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataPYPD, NSPR, MGRM, and PDEX HeadlinesRecent News About These CompaniesFY2026 Earnings Estimate for PolyPid Issued By HC WainwrightJune 14 at 2:17 AM | americanbankingnews.comPESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met ...June 11, 2025 | seekingalpha.comCraig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)June 11, 2025 | theglobeandmail.comPolyPid reports positive phase 3 surgical infection drug trialJune 11, 2025 | en.globes.co.ilNano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 TrialJune 11, 2025 | finance.yahoo.comPolyPid price target raised to $13 from $11 at H.C. WainwrightJune 11, 2025 | msn.comPolyPid (NASDAQ:PYPD) Price Target Raised to $13.00June 11, 2025 | americanbankingnews.comPolyPid shares surge on successful D-PLEX100 trial resultsJune 9, 2025 | in.investing.comBriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call TranscriptJune 9, 2025 | globenewswire.comPolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II TrialJune 9, 2025 | tipranks.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary EndpointsJune 9, 2025 | globenewswire.comRoth Capital Estimates PolyPid's Q2 Earnings (NASDAQ:PYPD)June 9, 2025 | americanbankingnews.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 8, 2025 | finance.yahoo.comPolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100June 6, 2025 | quiverquant.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEXâ‚₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 6, 2025 | globenewswire.comRoth Capital Initiates Coverage of PolyPid (PYPD) with Buy RecommendationJune 6, 2025 | msn.comPolyPid (NASDAQ:PYPD) Now Covered by Analysts at Roth CapitalJune 6, 2025 | americanbankingnews.comPolyPid at Lytham Partners: Strategic Advances and Financial StabilityMay 30, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYPD, NSPR, MGRM, and PDEX Company DescriptionsMonogram Orthopaedics NASDAQ:MGRM$2.70 +0.04 (+1.50%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.InspireMD NYSE:NSPR$2.44 +0.12 (+5.34%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Pro-Dex NASDAQ:PDEX$41.13 +1.57 (+3.97%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.PolyPid NASDAQ:PYPD$3.57 +0.16 (+4.69%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
